1. Association of renalase with clinical outcomes in hospitalized patients with COVID-19
- Author
-
Safdar, Basmah, Wang, Melinda, Guo, Xiaojia, Cha, Charles, Chun, Hyung J, Deng, Yanhong, Dziura, James, El-Khoury, Joe M, Gorelick, Fred, Ko, Albert I, Lee, Alfred I, Safirstein, Robert, Simonov, Michael, Zhou, Bin, and Desir, Gary V
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Good Health and Well Being ,Adult ,Aged ,COVID-19 ,Endothelium ,Female ,Hospitalization ,Humans ,Intensive Care Units ,Interleukin-6 ,Kaplan-Meier Estimate ,Male ,Middle Aged ,Monoamine Oxidase ,Proportional Hazards Models ,Respiration ,Artificial ,Retrospective Studies ,Risk Factors ,SARS-CoV-2 ,Severity of Illness Index ,General Science & Technology - Abstract
Renalase is a secreted flavoprotein with anti-inflammatory and pro-cell survival properties. COVID-19 is associated with disordered inflammation and apoptosis. We hypothesized that blood renalase levels would correspond to severe COVID-19 and survival. In this retrospective cohort study, clinicopathologic data and blood samples were collected from hospitalized COVID-19 subjects (March-June 2020) at a single institution tertiary hospital. Plasma renalase and cytokine levels were measured and clinical data abstracted from health records. Of 3,450 COVID-19 patients, 458 patients were enrolled. Patients were excluded if
- Published
- 2022